Abstract
Alcohol used disorder is a serious disease that accounts for almost 4% of the global burden of disease, for which currently available treatments have limited effectiveness. Since the early 2000s, baclofen, GABAB receptor agonist, is increasingly used in France with high-doses to treat alcohol dependence following its high media coverage and in response to patient expectations. Despite some studies demonstrating the effectiveness of baclofen in reducing alcohol consumption and maintaining alcohol abstinence, most randomized clinical trials in this context show conflicting and highly variable results, in some cases associated with serious side effects at high doses. However, because of its limited hepatic metabolism, baclofen is a particularly promising drug for people with liver disease, common in this population. It thus obtained its marketing authorization at the end of 2018 in the treatment of alcohol use disorder patients at the maximum dose of 80 mg/day. However, further studies are needed to better understand the variability of baclofen treatment response and thus to better adjust dosages in the overall management of the patient.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
